EP4209499

AMGEN INC.
Application Number
EP22211542A
Filing Date
Aug 12, 2016
Status
Granted And Under Opposition
Jul 5, 2024
Grant Date
Aug 7, 2024
External Links
Slate, Register

Biblio Summary

The patent EP4209499B1 was granted on Aug 7, 2024 by Amgen Inc. The patent is currently Granted And Under Opposition.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HEMSATH, LARSSep 23, 2024 N.A.

The table below shows the patents of Amgen Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3615066Formulations Of Human Anti-Rankl Antibodies, And Methods Of Using The SameDec 27, 20231
EP2301961Sclerostin EpitopesDec 13, 20231
EP3013318Stable Liquid Formulation Of Amg 416 (Velcalcetide)Apr 19, 20171

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.